Advances in Oral Cancer Diagnosis and Treatment

Oral cancer is a significant public health concern, with approximately 400,000 new cases reported annually worldwide. Its burden is particularly high in South Asia, driven by widespread use of tobacco, areca nut, and alcohol. One of the most critical challenges in managing oral cancer is the alarmingly low survival rate, largely due to late-stage detection and possibility of second primaries. Addressing the oral cancer burden requires a paradigm shift in prevention, diagnosis, and treatment through the integration of modern technology and innovative strategies. Traditional diagnostic methods often fail to the detect oral cancer in its early stages. These approaches are typically invasive, operator-dependent, and subject to interpretation bias, leading to poor prognoses. Modern technologies—ranging from artificial intelligence (AI) and genomics to immunotherapy and personalized medicine—present promising avenues for earlier and more accurate diagnosis, personalized treatment, and improved outcomes. Even though the main risk factors for oral cancer development are established as tobacco, areca nut, and alcohol, more and more cases without these risk factors are been reported. Therefore, identification of emerging Risk Factors is essential. Role of oral microbiome and HPV infection is a key area under investigation.[1] Human papillomavirus (HPV), especially strains 16 and 18, plays a growing role in oral and oropharyngeal cancers. These cancers are increasingly seen in non-smoking populations, underscoring the need for widespread HPV vaccination. Additionally, ongoing research highlights the role of the oral microbiome in the development of oral potentially malignant disorders (OPMDs) and oral cancer, suggesting new pathways for prevention and intervention. Primary prevention remains the cornerstone of oral cancer control. Efforts must focus on reducing risk factors through tobacco, areca nut and alcohol cessation programs, smokeless tobacco and areca nut control policies, and public awareness campaigns using newer strategies including the use of social media. Integration of HPV vaccination into national health strategies could further reduce incidence rates. Secondary prevention aims at early detection through screening. Community-based and opportunistic screening in dental clinics can help identify lesions early. The role of AI in risk stratification and lesion detection is expanding, offering scalable and efficient screening options. Conventional oral examination continues to be the frontline tool. However, its effectiveness can be enhanced using adjunctive aids like toluidine blue staining, brush biopsies, and light-based detection. Modern methods also include telemedicine-based consultations, and the use of blood and saliva for biomarker analysis.[2] Positive correlation between serum heavy metals and risk of oral cancer/OPMD has been identified recently.[3] Lab-on-a-chip (LOC) technology is a revolutionary point-of-care diagnostic platform, capable of detecting RNA and protein biomarkers with high accuracy using microfluidic systems. AI-based systems, meanwhile, are proving useful in early identification of OPMDs and oral cancer through mobile apps and histopathological image analysis. Digital health leverages information and communication technologies (ICTs) to improve health outcomes. It encompasses mobile health apps, teleconsultations, remote monitoring, and text-based health interventions. In oral oncology, digital health plays a crucial role in patient education, early detection, and long-term care. Tele-dentistry, a form of digital health, allows remote diagnosis, triage, and monitoring. While promising, its integration into routine practice faces challenges, including regulatory barriers and resistance from practitioners and patients. These issues must be addressed for wider adoption. Treatment of oral cancer requires a multimodal and multidisciplinary approach. Surgery remains the primary modality for non-metastatic cases, with less invasive techniques preferred for early-stage disease. Reconstructive options like free flap surgery, robotic-assisted procedures, and 3D anatomical modeling enhance outcomes and recovery. Advances in surgical oncology have focused on function preservation. Transoral robotic surgery (TORS) and laser microsurgery offer precise excision of tumors with minimal damage to surrounding tissues, thereby improving postoperative quality of life. TORS has been particularly effective in the treatment of oropharyngeal cancers and offers better access to difficult-to-reach areas. Use of robotic surgery has resulted in better quality of life.[4] Radiotherapy advancements—such as image-guided radiotherapy (IGRT), intensity-modulated radiotherapy (IMRT), and proton therapy—enable precise targeting while minimizing damage to healthy tissues. Chemotherapy has evolved with the introduction of targeted agents like EGFR inhibitors and immunotherapies (e.g., PD-1/PD-L1 inhibitors), offering better efficacy with fewer side effects. In addition, multiple newer therapies and innovations are emerging. Innovations like nanotechnology and gene therapy are paving the way for the future. These include nanoparticle drug delivery/nanoplatforms,[5] cancer vaccines, photodynamic therapy (PDT), and genomic profiling. Techniques such as CRISPR gene editing hold potential to the correct mutations at the molecular level. Biosensors are also being explored for real-time monitoring of cancer progression and treatment response. From generalized treatment, now focus is shifting towards personalized medicine.[6] post-treatment care is vital for recurrence monitoring, rehabilitation, and maintaining quality of life. AI-based prediction models, mobile apps, and telemedicine can streamline follow-up, provide patient education on self-examination, and support psychological well-being. Even though oral cancer research has advanced to greater extent, larger gaps is in knowledge still in existence. There is a glaring disparity in oral cancer research between high-income and low- and middle-income countries (LMICs). LMICs face unique challenges—socio-cultural factors, distinct etiologies, and different tumor behaviors. Building research capacity through funding, training, multidisciplinary collaboration, and effective use of local resources is critical to address these gaps. The future lies in integrating AI and big data for predictive analytics, developing gene therapies using CRISPR, and enhancing palliative care through digital tools. Strengthening research networks and encouraging postgraduate involvement are essential to advance innovation and improve patient care globally. In conclusion, early detection and prevention are pivotal in reducing oral cancer mortality. Traditional methods, though still relevant, are inadequate alone. Embracing modern diagnostic tools, AI, digital health, and novel therapies can transform oral cancer care. Global collaboration and investment in research, especially in LMICs, will be instrumental in shaping the future of oral oncology.